A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.

Trial Details

NCT ID
NCT07209449
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Abemaciclib
  • Elacestrant
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Age ≥18 years at the time of informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Patients must have received previous platinum-based chemotherapy
  • Patients may have received no more than 2 prior lines of therapy for management of endometrial carcinoma. This includes platinum-based chemotherapy…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →